FDA Approves Humira
FDA Approves Humira for Rheumatoid Arthritis
Humira is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for reducing the signs and symptoms, inducing major clinical response, slowing the progression of joint damage, and improving physical function in adult patients with moderate to severe rheumatoid arthritis.Posted: December 2002
Related Articles:
- Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis - February 22, 2008
- Abbott's Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis - January 22, 2008
- Humira (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease - February 27, 2007
- Humira Receives FDA Approval for Treatment of Ankylosing Spondylitis - July 31, 2006
- Humira Receives FDA Approval for Psoriatic Arthritis - October 4, 2005
